Omega-3-fatty acids: Do they prevent cardiovascular disease?

IF 6.1 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-05-01 DOI:10.1016/j.beem.2022.101681

R. Preston Mason PhD, MBA (President, Elucida Research Faculty) , Samuel C.R. Sherratt BS (Doctoral Candidate in Biochemistry) , Robert H. Eckel MD (Professor of Medicine Emeritus)

{"title":"Omega-3-fatty acids: Do they prevent cardiovascular disease?","authors":"R. Preston Mason PhD, MBA (President, Elucida Research Faculty) , Samuel C.R. Sherratt BS (Doctoral Candidate in Biochemistry) , Robert H. Eckel MD (Professor of Medicine Emeritus)","doi":"10.1016/j.beem.2022.101681","DOIUrl":null,"url":null,"abstract":"<div><p>Despite cardiovascular disease (CVD) reductions with high-intensity statins, there remains residual risk among patients with metabolic disorders. Alongside low-density lipoproteins (LDL-C), elevated triglycerides (TG) are associated with incident CVD events. Omega-3 fatty acids (n3-FAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower TG levels, but their ability to reduce CV risk has been highly inconsistent. Trials using icosapent ethyl (IPE), a purified EPA ethyl ester, produced reductions in CVD events and atherosclerotic plaque regression compared with mixed EPA/DHA formulations despite similar TG-reductions. The separate effects of EPA and DHA on tissue distribution, oxidative stress, inflammation, membrane structure and endothelial function may contribute to these discordant outcomes. Additional mechanistic trials will provide further insights into the role of n3-FAs in reducing CVD risk beyond TG lowering.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 3","pages":"Article 101681"},"PeriodicalIF":6.1000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best practice & research. Clinical endocrinology & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521690X22000689","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 3

Abstract

Despite cardiovascular disease (CVD) reductions with high-intensity statins, there remains residual risk among patients with metabolic disorders. Alongside low-density lipoproteins (LDL-C), elevated triglycerides (TG) are associated with incident CVD events. Omega-3 fatty acids (n3-FAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower TG levels, but their ability to reduce CV risk has been highly inconsistent. Trials using icosapent ethyl (IPE), a purified EPA ethyl ester, produced reductions in CVD events and atherosclerotic plaque regression compared with mixed EPA/DHA formulations despite similar TG-reductions. The separate effects of EPA and DHA on tissue distribution, oxidative stress, inflammation, membrane structure and endothelial function may contribute to these discordant outcomes. Additional mechanistic trials will provide further insights into the role of n3-FAs in reducing CVD risk beyond TG lowering.

查看原文本刊更多论文

-3脂肪酸:它们能预防心血管疾病吗?

尽管高强度他汀类药物减少了心血管疾病（CVD），但代谢紊乱患者仍存在残余风险。除了低密度脂蛋白（LDL-C）外，甘油三酯（TG）升高也与心血管疾病事件有关。ω-3脂肪酸（n3-FA），特别是二十碳五烯酸（EPA）和二十二碳六烯酸（DHA），可以降低TG水平，但它们降低心血管疾病风险的能力一直非常不一致。与EPA/DHA混合制剂相比，使用二十碳五烯酸乙酯（IPE）（一种纯化的EPA乙酯）的试验降低了CVD事件和动脉粥样硬化斑块消退，尽管TG降低相似。EPA和DHA对组织分布、氧化应激、炎症、膜结构和内皮功能的单独影响可能导致这些不一致的结果。除降低TG外，其他机制试验将进一步深入了解n3-FA在降低CVD风险方面的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best practice & research. Clinical endocrinology & metabolism 医学-内分泌学与代谢

CiteScore

11.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Best Practice & Research Clinical Endocrinology & Metabolism is a serial publication that integrates the latest original research findings into evidence-based review articles. These articles aim to address key clinical issues related to diagnosis, treatment, and patient management. Each issue adopts a problem-oriented approach, focusing on key questions and clearly outlining what is known while identifying areas for future research. Practical management strategies are described to facilitate application to individual patients. The series targets physicians in practice or training.